Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis: A novel variant of BRAF inhibitor associated panniculitis with histiocytoid infiltrate of immature neutrophils

Neutrophilic panniculitis is an infrequent but characteristic adverse event under therapy with BRAF inhibitors (BRAFi). Since the approval of vemurafenib for treatment of metastatic melanoma in 2011, only two cases of neutrophilic panniculitis in malignancies other than melanoma have been published....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Biol Ther
Egile Nagusiak: Richarz, Nina Anika, Puig, Luis, Pérez, Noelia, Cuadra-Urteaga, Jose, Elez, Elena, Fernández-Figueras, Maria Teresa
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2018
Gaiak:
Bedside to Bench Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6370375/
https://ncbi.nlm.nih.gov/pubmed/30426827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1529113
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak